Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.

Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.

This prospective cohort of patients, receiving pre exposure prophylaxis by Anti-SARS-CoV-2 Monoclonal Antibodies, is designed to evaluate the treatment protection against SARS-CoV-2 variants of concerns

Inclusion Criteria:

• Adults (18 years-old or more)
• Patient who received the first administration of Evusheld at 300 mg for less than 4 months and should receive a second dose, according to French recommendations OR Patient scheduled to receive or having received less than a month ago an injection of anti-SARS-CoV-2 monoclonal antibodies, as pre-exposure prophylaxis at 600 mg, according to the French SARS-CoV-2 RT recommendations
• qPCR negative at baseline
• SARS-CoV-2 RT-qPCR Negative at inclusion
• Patients who remain seronegative after a complete COVID-19 vaccination schedule
• Immunocompromised patients :

Hemopathy : chronic lymphoid leukemia, non hodgkin's lymphoma, HSCT Transplant recipient : kidney, liver, lungs Patients receiving anti CD20 or others immunosuppressor

• Life expectancy > 3 months
• Social security affiliation
• Lack of a legal protection measure
• Signed informed consent

Exclusion Criteria:

• Participation to another clinical study
• State medical aid
• Ongoing or scheduled plasmapheresis or immunoadsorption
• Pregnant / lactating woman
• Patient whose isolation period is underway following contact with a confirmed case of SARS-CoV2 infection
• Hypersensitivity to one of the active substances or to one of the excipients